Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

Bristol Motor Speedway officials have called a press conference for Wednesday, April 25, to release the details about upcoming changes to the track. According to the news release, Speedway Motorsports ...

U.S. pharmaceutical company Bristol Myers Squibb (BMS) on Friday became the latest organization to file a legal challenge against the the Medicare drug price negotiation program established by the ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Bristol Myers Squibb is yet another example of a Big Pharma company pledging a multibillion dollar investment in the U.S. as the Trump administration tries to woo drugmakers to boost their domestic ...

Michael J. Tougias, a Massachusetts-born adventure writer, visited Bourne Middle School (BMS) on November 13 to explain the ...